Can an arthritis drug tame severe COVID-19?
NCT ID NCT04412772
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug tocilizumab (Actemra) in hospitalized adults with severe COVID-19 and signs of inflammation. Participants received either the drug or a placebo, with the goal of improving clinical status by day 28. The trial was terminated early after enrolling only 20 of the planned 300 patients, limiting what can be concluded.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tocilizumab (Actemra)
- What this could lead to
- If successful, this could provide a treatment option for severe COVID-19 by reducing inflammation and improving recovery.
- What could go wrong
- The trial was terminated early with only 20 participants, so results are limited. Tocilizumab may not work for all patients and carries risks like infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Queen's Medical Center
Honolulu, Hawaii, 96813, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?